Back to search

Peptide record

TPDB42722

mPNC-NLS Anticancer standard
21 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB42722
mPNC-NLS
Anticancer
Cancer-related peptides
CancerPPD 2.0
standard
No
A 21-aa standard natural anticancer peptide sequence curated from CancerPPD 2.0, with an available 3D structural model.
Sequence
QETFSDLWKLLVQRKRQKLMP
Physicochemical Analysis
C120H198N34O31S1
ANCGHIY
L
2645.16
10.81
5
2
8
+3
4.92
-0.862
88.10
Mammalian: 0.8 hour Yeast: 10 min E.coli: >10 hour
5500
207.93
5
Residue Composition
number
0
A
2
R
0
N
1
D
0
C
1
E
3
Q
0
G
0
H
0
I
4
L
3
K
1
M
1
F
1
P
1
S
1
T
1
W
0
Y
1
V
Amino Acid Distribution
A: 0 R: 2 N: 0 D: 1 C: 0 E: 1 Q: 3 G: 0 H: 0 I: 0 L: 4 K: 3 M: 1 F: 1 P: 1 S: 1 T: 1 W: 1 Y: 0 V: 1
Chemical Descriptors
21
C120H198N34O31S1
2645.16
10.81
+3
4.92
-0.862
Free
L
Linear
Free
Anticancer
Synthetic
Evidence Records 3 records
Evidence 1 Activity

Activity

IC50
IC50 = 44.9 µM
Anticancer
44.9 µM

Target

Lung Cancer
A-549
Lung

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2023

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50 = 56.9 µM
Anticancer
56.9 µM

Target

Brain Tumor
U-87
Brain

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2023
Evidence 3 Activity

Activity

IC50
IC50 = 45 µM
Anticancer
45 µM

Target

Lung Cancer
A-549
Lung

Assay & Model

Cytotoxicity assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2023